Donate

Clinical Trials

WHAT IS A CLINICAL TRIAL

A clinical trial is a type of research study that aims to explore whether a medical treatment is safe and effective for humans.

DO YOU NEED A CLINICAL TRIAL?

If you have liposarcoma progression despite the use of standard therapies and surgery, you or your doctor may want to investigate a clinical trial as an option for your treatment plan. While clinical trials are technically considered research, many liposarcoma patients have benefited from participation. Each clinical trial is designed for a specific purpose or condition.

WHAT ARE THE BENEFITS?

  • The option of gaining access to new treatments after standard therapy fails.
  • The opportunity to be the first to benefit from a new method under study.
  • Receiving treatment at a major liposarcoma trial center.
  • Close monitoring, advice, care, and support by a research team who has a better understanding of your disease or condition.
  • The chance of helping future liposarcoma patients by contributing to medical research.


WHAT ARE THE RISKS?

  • The new drug may not work for you.
  • There may be unpleasant side effects as a response to the experimental treatment.
  • Additional testing, time, and travel may be required.
  • Some costs may not be covered by insurance companies.


CURRENT CLINICAL TRIALS:

BTX-A51 in Patients with Liposarcoma

  • Locations Brigham and Women’s Hospital, Boston, Massachusetts, 02215, United States; Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States
  • Status RECRUITING
  • CONDITIONS Liposarcoma, Recurrent Liposarcoma, Metastatic Liposarcoma, Unresectable Liposarcoma, MDM2 Gene Amplification
  • INTERVENTIONS DRUG: BTX-A51
  • Brief Summary: This study is testing if the recommended dose of BTX-A51 is safe and tolerable in participants with liposarcoma… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06414434

Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone. (TRABEPIO)

  • Locations Fondazione IRCCS Istituto Nazionale Tumori, Milano, MI, 20133, Italy
  • Status RECRUITING
  • CONDITIONS Liposarcoma, Myxoid; liposarcoma, Dedifferentiated; Liposarcoma, Round Cell
  • INTERVENTIONS DRUG: Trabectedin; DRUG: Pioglitazone Oral Product
  • Brief Summary: This is a phase 2 study conducted in two sequential stages… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04794127

A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)

  • Locations Oslo University Hospital HF, Oslo, Norway (NOT YET RECRUITING); Sahlgrenska University Hospital, Göteborg, Sweden; Skane University Hospital, Lund, Sweden
  • Status RECRUITING
  • CONDITIONS Dedifferentiated Liposarcoma
  • INTERVENTIONS DRUG: Pemigatinib; DRUG: Retifanlimab
  • Brief Summary: Dedifferentiated liposarcomas (DDLPS) are aggressive soft tissue sarcomas… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06389799

Open-Label Study of the CDK4/​6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas

  • Locations Mayo Clinic Hospital, Phoenix, Arizona, 85054, United States; City of Hope, Duarte, California, 91010, United States; Mayo Clinic Florida, Jacksonville, Florida, 32224, United States; University of Miami, Miami, Florida, 33136, United States; University of Michigan, Ann Arbor, Michigan, 48109, United States; Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States; Seidman Cancer Center, University Hospitals, Cleveland, Ohio, 44106, United States; The Ohio State University, Columbus, Ohio, 43210, United States; Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States
  • Status RECRUITING
  • CONDITIONS Liposarcoma, Dedifferentiated
  • INTERVENTIONS DRUG: SPH4336
  • Brief Summary: Study SPH4336-US-01 is an open-label (no placebo), multicenter clinical trial to evaluate the safety, blood levels (pharmacokinetics) and preliminary anti-tumor effects of SPH4336… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05580588

International Prospective Registry on Local Treatment Approaches in MLS

  • Locations The Netherlands Cancer Institute, Amsterdam, 1066CX, Netherlands
  • Status RECRUITING
  • CONDITIONS Myxoid Liposarcoma
  • INTERVENTIONS PROCEDURE: Surgery; RADIATION: Preoperative RT 36Gy; RADIATION: Preoperative RT 50Gy; RADIATION: Postoperative RT 50-66Gy; RADIATION: RT 36Gy
  • Brief Summary: To prospectively study commonly used local treatment approaches in Myxoid Liposarcoma (MLS)… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04699292

Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (TRASTS)

  • Locations Institut Bergonie, Bordeaux, 33000, France; Centre Leon Berard, Lyon, France; Istituto Clinico Humanitas, Rozzano, Milan, 20089 (NOT YET RECRUITING), Italy; Centro di Referimento Ocologico, Aviano, 33081, Italy (NOT YET RECRUITING); Istituto Ortopedico Rizzoli, Bologna, 40136, Italy (NOT YET RECRUITING); Candiolo Cancer Institute, Candiolo, 10060, Italy; Istituto Nazionale dei Tumori, Milan, 20133, Italy; Hospital Miguel Servet, Zaragoza, Aragon, 50009, Spain; Hospital Sant Pau, Barcelona, Cataluña, 08041, Spain; Hospital Son Espases, Palma de Mallorca, Mallorca, 07010, Spain; Hospital Universitario Canarias, San Cristobal de la Laguna, Tenerife, 38320, Spain; Hospital Vall d’Hebron, Barcelona, 08035, Spain; Hospital Puerta de Hierro, Madrid, 28006, Spain; Hospital Universitario Gregorio Maranon, Madrid, 28007, Spain; Hospital Uniersitario La Paz, Madrid, 28046, Spain; Jimenez Di­az Foundation University Hospital, Madrid, Spain; Hospital Virgen del Roci­o, Sevilla, 41013, Spain
  • Status RECRUITING
  • CONDITIONS Liposarcoma, Myxoid; Sarcoma, Soft Tissue; Leiomyosarcoma; Liposarcoma; Pleomorphic Liposarcoma
  • INTERVENTIONS DRUG: Trabectedin; RADIATION: Radiotherapy
  • Brief Summary: Phase I-II trial that combines trabectedin plus radiotherapy for tumor reduction response measure in four cohorts of patients… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT02275286

SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma

  • Locations University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado, 80045, United States; Mayo Clinic Florida, Jacksonville, Florida, 32224, United States; Northwestern University, Chicago, Illinois, 60611, United States; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, 02114, United States; Washington University School of Medicine, Saint Louis, Missouri, 63129, United States; Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States; Duke University, Durham, North Carolina, 27710, United States; Oregon Health & Science University, Portland, Oregon, 97239, United States; University of Washington, Seattle, Washington, 98109, United States
  • Status RECRUITING
  • CONDITIONS Advanced Dedifferentiated Liposarcoma
  • INTERVENTIONS DRUG: Abemaciclib; DRUG: Placebo
  • Brief Summary: This is a Phase 3 randomized double-blind study of abemaciclib versus placebo. Patients with progression of disease will cross over to open label abemaciclib… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04967521

A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma

  • Locations Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, 07920, United States; Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, 07748, United States; Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, 07645, United States; Memorial Sloan Kettering Suffolk – Commack (Limited Protocol Activities), Commack, New York, 11725, United States; Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, 10604, United States; Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States; Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre, New York, 11553, United States
  • Status RECRUITING
  • CONDITIONS Dedifferentiated Liposarcoma; Soft Tissue Sarcoma; Sarcoma,Soft Tissue; Sarcoma; Recurrent Dedifferentiated Liposarcoma; Unresectable Dedifferentiated Liposarcoma; Metastatic Dedifferentiated Liposarcoma
  • INTERVENTIONS DRUG: Etrumadenant; DRUG: Zimberelimab
  • Brief Summary: Participants will have a diagnosis of dedifferentiated liposarcoma (DDLS) that has spread beyond its original location (advanced)… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05886634

APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors

  • Locations Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China; Cancer Hospital of The University of Chinese Academy of Sciences, Hangzhou, Zhejiang, 310005, China; Shanghai East Hospital (East Hospital affiliated to Tongji University), Shanghai, China
  • Status RECRUITING
  • CONDITIONS Liposarcoma; Advanced Solid Tumor
  • INTERVENTIONS DRUG: APG-115; DRUG: Toripalimab
  • Brief Summary: Part 1 is a phase Ib standard “3 + 3” design, will be employed to determine the MTD of APG-115 by assessing the DLT of APG-115 in combination with PD-1 inhibitor(toripalimab) in advanced solid tumors. Part 2 is a Simon two-stage phase II study design. At RP2D of APG-115 in combination with toripalimab in advanced liposarcoma, approximately 34 patients will be treated with the combination until disease progression, unacceptable toxicity, or another discontinuation criterion is met… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04785196

Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas (ESPACE)

  • Locations Institut du Cancer de Montpellier – Val d’Aurelle, Montpellier, 34298, France
  • Status RECRUITING
  • CONDITIONS Liposarcoma; Atypical Lipomatous Tumor
  • INTERVENTIONS DIAGNOSTIC_TEST: Blood sampling
  • Brief Summary: The main objective of this project is to identify a new non-invasive biological test for the diagnosis of LPS by measuring circulating serine levels. The current gold standard is the detection of Mdm2 amplification by the FISH…More information and eligibility requirements can be found here: STUDY: NCT04224064

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/​Round Cell Liposarcoma

  • Locations See link below for various location options.
  • Status RECRUITING
  • CONDITIONS Synovial Sarcoma; Myxoid Liposarcoma
  • INTERVENTIONS GENETIC: afamitresgene autoleucel (previously ADP-A2M4)
  • Brief Summary: This is a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A\*02 eligible and MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1, 2 and 3 ) or MRCLS (Cohort 1) … For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04044768

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma (STRASS2)

  • Locations See link below for various location options.
  • Status RECRUITING
  • CONDITIONS Retroperitoneal Sarcoma; Liposarcoma; Leiomyosarcoma
  • INTERVENTIONS PROCEDURE: Surgery; DRUG: Preoperative chemotherapy
  • Brief Summary: This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04031677

Genomic Risk in Retroperitoneal Sarcoma

  • Locations Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States
  • Status RECRUITING
  • CONDITIONS Retroperitoneal Liposarcoma; Soft Tissue Sarcoma
  • INTERVENTIONS OTHER: Biospecimen sample collection during standard-of-care surgery
  • Brief Summary: The protocol intends to explore the biology which may underlie recurrences of retroperitoneal liposarcoma. Surgery remains the only curative intent intervention for this disease…More information and eligibility requirements can be found here: STUDY: NCT06436846

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

  • Locations St. Jude Children’s Research Hospital, Memphis, Tennessee, 38105, United States
  • Status RECRUITING
  • CONDITIONS Non-rhabdomyosarcoma; Adipocytic Neoplasm; Liposarcoma
  • INTERVENTIONS PROCEDURE: Surgical resection; RADIATION: Proton beam radiation therapy; DRUG: Pazopanib; DRUG: Ifosfamide; DRUG: Doxorubicin; DRUG: Selinexor
  • Brief Summary: The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS)… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06239272

Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (DOSa)

  • Locations M D Anderson Cancer Center, Houston, Texas, 77030, United States
  • Status RECRUITING
  • CONDITIONS Metastatic Angiosarcoma; Metastatic Dedifferentiated Liposarcoma; Metastatic Osteosarcoma; Recurrent Angiosarcoma; Recurrent Dedifferentiated Liposarcoma; Recurrent Osteosarcoma; Refractory Dedifferentiated Liposarcoma; Refractory Osteosarcoma
  • INTERVENTIONS BIOLOGICAL: Durvalumab; BIOLOGICAL: Oleclumab
  • Brief Summary: This phase II trial investigates how well oleclumab and durvalumab work in treating patients with sarcoma that has come back (recurrent) or does not respond to treatment (refractory) or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as oleclumab and durvalumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04668300

Phase I/​Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

  • Locations MD Anderson Cancer Center, Houston, Texas, 77030, United States
  • Status RECRUITING
  • CONDITIONS Synovial Sarcoma; Myxoid/Round Cell Liposarcoma
  • INTERVENTIONS DRUG: Fludarabine phosphate; DRUG: NY-ESO-1 TCR/IL-15 NK; DRUG: Cyclophosphamide
  • Brief Summary: The goal of this clinical research study is to find a recommended dose of donated NK cells that can be given along with chemotherapy to patients with advanced cancers. The safety and effects of this therapy will also be studied… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06083883

Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma

  • Locations See link below for various location options.
  • Status RECRUITING
  • CONDITIONS Advanced Dedifferentiated Liposarcoma; Locally Advanced Dedifferentiated Liposarcoma; Metastatic Dedifferentiated Liposarcoma; Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Unresectable Dedifferentiated Liposarcoma
  • INTERVENTIONS DRUG: Palbociclib; BIOLOGICAL: Cemiplimab; PROCEDURE: Magnetic Resonance Imaging; PROCEDURE: Computed Tomography; PROCEDURE: Biospecimen collection; OTHER: Questionnaire Administration
  • Brief Summary: This phase II trial compares the effect of treatment with palbociclib alone to treatment with palbociclib plus cemiplimab for treating patients with dedifferentiated liposarcoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) … For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05694871

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i)

  • Locations See link below for various location options.
  • Status RECRUITING
  • CONDITIONS Liposarcoma; Prostate Cancer; Breast Neoplasms; Adenocarcinoma of Lung
  • INTERVENTIONS DRUG: PF-07220060; COMBINATION_PRODUCT: Letrozole; COMBINATION_PRODUCT: Fulvestrant; DRUG: Midazolam; COMBINATION_PRODUCT: Enzalutamide
  • Brief Summary: This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and then in combination with endocrine therapy… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04557449

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

  • Locations Texas Children’s Hospital, Houston, Texas, 77030, United States
  • Status RECRUITING
  • CONDITIONS Liver Cancer; Rhabdomyosarcoma; Malignant Rhabdoid Tumor; Liposarcoma; Wilms Tumor; Yolk Sac Tumor
  • INTERVENTIONS GENETIC: CARE T cells; DRUG: Cytoxan; DRUG: Fludara
  • Brief Summary: Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This research study uses special immune system cells called CARE T cells, a new experimental treatment … For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04715191

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

  • Locations Texas Children’s Hospital, Houston, Texas, 77030, United States
  • Status RECRUITING
  • CONDITIONS Liver Cancer; Rhabdomyosarcoma; Malignant Rhabdoid Tumor; Liposarcoma; Wilms Tumor; Yolk Sac Tumor
  • INTERVENTIONS GENETIC: AGAR T cells
  • Brief Summary: Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This research study uses special immune system cells called AGAR T cells, a new experimental treatment… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04377932

BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (DUET-1)

  • Locations Baylor Scott and White Research Institute, Dallas, Texas, 75246, United States; University of Texas MD Anderson Cancer Center, Houston, Texas, 77030-4008, United States; Froedtert and Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States
  • Status RECRUITING
  • CONDITIONS Hepatocellular Carcinoma; Squamous Cell Carcinoma of the Lung; Merkel Cell Carcinoma; Myxoid/Round Cell Liposarcoma
  • INTERVENTIONS BIOLOGICAL: CAR-GPC3 T Cells
  • Brief Summary: This is a first-in-human (FIH), Phase 1/2, open-label, multicenter study to assess safety and determine the recommended Phase 2 dose (RP2D) of BOXR1030 administration after lymphodepleting chemotherapy (LD chemotherapy) in subjects with glypican-3 positive (GPC3+) advanced solid tumors… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05120271

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

  • Locations Krankenhaus Nordwest, Frankfurt, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Universitatsklinikum Tubingen, Tubingen, Germany
  • Status RECRUITING
  • CONDITIONS Melanoma (Skin); Triple-Negative Breast Cancer; Non-Small Cell Lung Cancer; Synovial Sarcoma; Myxoid Liposarcoma; Colorectal Cancer
  • INTERVENTIONS DRUG: PeptiCRAd-1; DRUG: Cyclophosphamide; DRUG: Pembrolizumab
  • Brief Summary: This study is being conducted to explore the immunological mechanism of action of Peptide-coated Conditionally Replicating Adenovirus-1 (PeptiCRAd-1) plus Checkpoint inhibitor (CPI) therapy in multiple cancer types, as well as to obtain early information on the safety of this combination therapy… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05492682

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

  • Locations National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, 20892, United States; Dana-Farber – Harvard Cancer Center LAO, Boston, Massachusetts, 02115, United States; Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109, United States (SUSPENDED); University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, 15232, United States; M D Anderson Cancer Center, Houston, Texas, 77030, United States
  • Status RECRUITING
  • CONDITIONS Metastatic Dedifferentiated Liposarcoma; Metastatic Leiomyosarcoma; Metastatic Myxofibrosarcoma; Metastatic Sarcoma; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Unresectable Dedifferentiated Liposarcoma; Unresectable Leiomyosarcoma; Unresectable Myxofibrosarcoma; Unresectable Sarcoma; Unresectable Synovial Sarcoma; Unresectable Undifferentiated Pleomorphic Sarcoma
  • INTERVENTIONS PROCEDURE: Biopsy; PROCEDURE: Biospecimen Collection; PROCEDURE: Computed Tomography; PROCEDURE: Magnetic Resonance Imaging; DRUG: Pegylated Liposomal Doxorubicin Hydrochloride; DRUG: Peposertib
  • Brief Summary: This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarcoma that has spread from where it first started, to other places in the body (metastatic), or cannot be removed by surgery (unresectable) and for which no known cure is available (advanced)… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05711615

A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

  • Locations See link below for various location options.
  • Status RECRUITING
  • CONDITIONS Advanced Solid Tumors
  • INTERVENTIONS DRUG: SPH4336; DRUG: Cadonilimab
  • Brief Summary: This is a randomized, Open-label, Phase Ib/IIa study to evaluate the efficacy and safety of SPH4336 monotherapy or in combination with Cadonilimab in the patients with selected advanced solid tumors.… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05944224

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors

  • Locations Houston Methodist Hospital, Houston, Texas, 77030, United States
  • Status RECRUITING
  • CONDITIONS Liver Cell Carcinoma; Solid Tumor; Wilms Tumor; Malignant Rhabdoid Tumor; Yolk Sac Tumor; Rhabdomyosarcoma; Liposarcoma; Embryonal Sarcoma of the Liver
  • INTERVENTIONS GENETIC: CATCH T cells
  • Brief Summary: Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This research study uses special immune system cells called CATCH T cells, a new experimental treatment… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05103631

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

  • Locations See link below for various location options.
  • Status RECRUITING
  • CONDITIONS Locally Advanced Extraskeletal Myxoid Chondrosarcoma; Locally Advanced Leiomyosarcoma; Locally Advanced Liposarcoma; Locally Advanced Undifferentiated Pleomorphic Sarcoma; Locally Advanced Unresectable Soft Tissue Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma
  • INTERVENTIONS PROCEDURE: Biopsy; PROCEDURE: Biospecimen Collection; DRUG: Cabozantinib; PROCEDURE: Computed Tomography; BIOLOGICAL: Ipilimumab; PROCEDURE: Magnetic Resonance Imaging; BIOLOGICAL: Nivolumab
  • Brief Summary: This phase II trial compares the effect of immunotherapy with ipilimumab and nivolumab alone to their combination with cabozantinib in treating patients with soft tissue sarcoma that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced)… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05836571

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

  • Locations HonorHealth Research Institute, Scottsdale, Arizona, 85258, United States; NEXT Austin, Austin, Texas, 78758, United States; NEXT Oncology, San Antonio, Texas, 78229, United States
  • Status RECRUITING
  • CONDITIONS Cancer; Tumor, Solid; Malignant Neoplasm; Metastatic Cancer; Advanced Solid Tumor; Non Small Cell Lung Cancer; Melanoma; Head and Neck Squamous Cell Carcinoma; Leiomyosarcoma; Liposarcoma
  • INTERVENTIONS DRUG: OR2805; DRUG: Cemiplimab; DRUG: Docetaxel
  • Brief Summary: This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805 administered as a monotherapy and in combination with anti-cancer agents in subjects with advanced solid tumors… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05094804

NM32-2668 in Adult Patients With Selected Advanced Solid Tumors

  • Locations USC Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States; Duke University, Durham, North Carolina, 27710, United States; Cleveland Clinic, Cleveland, Ohio, 44195, United States; University of Pittsburgh Medical Center (UPMC) – Hillman Cancer Center, Pittsburgh, Pennsylvania, 15232, United States; Lifespan Cancer Institute at Rhode Island Hospital, Providence, Rhode Island, 02903, United States; Mary Crowley Cancer Research, Dallas, Texas, 75230, United States
  • Status RECRUITING
  • CONDITIONS Ovarian Carcinoma; Fallopian Tube Carcinoma; Peritoneal Carcinoma; Endometrial Cancer; Adenocarcinoma of Lung; Triple Negative Breast Cancer; Liposarcoma; Leiomyosarcoma; Mesothelioma, Malignant; Adenocarcinoma – Gastroesophageal Junction (GEJ); Adenocarcinoma of the Stomach; Melanoma, Malignant; Renal Cell Carcinoma
  • INTERVENTIONS BIOLOGICAL: NM32-2668
  • Brief Summary: This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT06299163

Study of the CHK1 Inhibitor BBI-355, an EcDNA-directed Therapy (ecDTx), in Subjects with Tumors with Oncogene Amplifications (POTENTIATE)

  • Locations See link below for various location options.
  • Status RECRUITING
  • CONDITIONS Non-small Cell Lung Cancer; Non-Small Cell Lung Adenocarcinoma; Non-Small Cell Squamous Lung Cancer; Head and Neck Squamous Cell Carcinoma; Esophageal Cancer; Gastric Cancer; Breast Cancer; Bladder Cancer; Ovarian Cancer; Endometrial Cancer; Liposarcoma
  • INTERVENTIONS DRUG: BBI-355; DRUG: Erlotinib; DRUG: Futibatinib
  • Brief Summary: BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx). This is a first-in-human, open-label, 3-part, Phase 1/2 study to determine the safety profile and identify the maximum tolerated dose and recommended Phase 2 dose of BBI-355 administered as a single agent or in combination with select therapies… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT05827614

The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)

  • Locations Teton Cancer Institute, Idaho Falls, Idaho, 83404, United States; Oncology and Hematology of South Texas, Laredo, Texas, 78041, United States
  • Status RECRUITING
  • CONDITIONS Adenocarcinoma; Adenocystic Carcinoma; Anal Cancer; Appendix Cancer; Brain Tumor; Glioblastoma; Astrocytoma; Bile Duct Cancer; Cholangiocarcinoma; Bladder Cancer; Bone Cancer; Synovial Sarcoma; Chondrosarcoma; Liposarcoma; Sarcoma, Kaposi; Sarcoma,Soft Tissue; Sarcoma; Osteosarcoma; CNS Cancer; Brain Stem Neoplasms; Breast Cancer; Cervical Cancer; Colorectal Cancer; Rectal Cancer; Colon Cancer; Esophageal Cancer; Esophagus Cancer; Cancer of Colon; Pancreatic Cancer; Cancer of Pancreas; Testis Cancer; Testicular Cancer; Ureter Cancer; Renal Cell Carcinoma; Kidney Cancer; Gestational Trophoblastic Tumor; Head and Neck Neoplasms; Parotid Tumor; Larynx Cancer; Tongue Cancer; Pharynx Cancer; Salivary Gland Cancer; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia; Multiple Myeloma; Non Hodgkin Lymphoma; Carcinoid Tumor; Lung Cancer; Neuroendocrine Tumors; Mesothelioma; Thyroid Cancer; Parathyroid Neoplasms; Adrenal Cancer; Small Bowel Cancer; Stomach Cancer; Liver Cancer; Hepatic Cancer; Melanoma; Skin Cancer; Unknown Primary Tumors; Uterine Cancer; Fallopian Tube Cancer; Ovarian Cancer; Prostate Cancer; Vaginal Cancer; Penile Cancer; Vulvar Cancer; Waldenstrom Macroglobulinemia; Cancer, Advanced; Thymus Cancer; Nasopharyngeal Carcinoma; Multiple Endocrine Neoplasia; Pheochromocytoma; Small Cell Carcinoma; Pulmonary Carcinoma
  • INTERVENTIONS DIAGNOSTIC_TEST: Biomarker Testing (L); DRUG: Systemic Treatment (T); OTHER: Patient Reported Outcomes (P)
  • Brief Summary: This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation. It will also create reusable infrastructure to allow creation or affiliation with many additional RWD/RWE efforts both prospective and retrospective in nature… For up-to-date information including open recruiting locations and eligibility, click here: STUDY: NCT04028479